939307
Protein delivery system
Human BDNF, PODS®
Synonym(s):
PODS®
biological source
(Spodoptera frugiperda (Sf9) cell culture)
Quality Level
form
(monodisperse crystals)
packaging
1 ea of 25 μg
technique(s)
: suitable using 3D bioprinting | cell culture
impurities
<0.06 EU/mL Endotoxin
color
colorless
storage temp.
2-8°C
Looking for similar products? Visit Product Comparison Guide
General description
Protein delivery system, PODS Human BDNF contains the polyhedrin protein co-crystalized with human Brain-derived neurotrophic factor (BDNF) which a protein that plays a crucial role in the growth, development, and maintenance of neurons in the brain. BDNF binds two receptors, the low-affinity nerve growth factor receptor (LNGFR) and the tropomyosin receptor kinase B (TrkB), to support neuron growth and survival. BDNF expression in the hippocampus is essential for long-term memory storage and learning. Some protein domains of BDNF are identical with those of NGF and another neurotrophic factor, designated NT-3 (Neurotrophin-3). Human, mouse, rat, and pig BDNF are cross-reactive.
Application
PODS are composed of a bioactive cargo protein within a polyhedrin crystal lattice, with polyhedrin as the main protein. The 25 µg SKU size indicates the amount of bioactive cargo, typically 0.5% to 5% of the total protein. For instance, a 25 µg SKU at a 2% cargo loading contains 1.25 mg of total protein. PODS enable sustained release of cargo proteins when proteases degrade the polyhedrin scaffold. Growth factors are not bioavailable until released, and their concentration in media depends on the amount added and the release rate. In 10% serum, peak levels are usually reached within 24-48 hours, with about 20% of the cargo becoming soluble.
PODS often require lower concentrations than conventional growth factors, as they maintain effective levels. Pre-incubating with serum or proteases enhances availability, while conventional factors can be added for immediate effects. Optimal amounts should be determined empirically.
PODS often require lower concentrations than conventional growth factors, as they maintain effective levels. Pre-incubating with serum or proteases enhances availability, while conventional factors can be added for immediate effects. Optimal amounts should be determined empirically.
Features and Benefits
- Protein delivery system, PODS Human BDNF comes with molecular weight of 37.6 kDa, length 164 aa, with endotoxin level of <0.06 EU/ml as measured by gel clot LAL assay. PODS co-crystals may be reconstituted at 200 million co-crystals/ml in sterile PBS. 20% glucose has a buoyant density closer to PODS co-crystals and can be useful for aliquoting.
- This product is produced with no animal derived raw products. All processing and handling employs animal free equipment and animal free protocols. PODS co-crystals are highly stable when stored in aqueous solution (pH range 6 - 8).
- PODS provides durability, stability AND sustained release, addressing the limitations of conventional and enabling researchers to effortlessly control and manipulate cells in 2D and 3D culture as well as in-vivo.
Legal Information
PODS is a registered trademark of Cell Guidance Systems Ltd
Storage Class Code
11 - Combustible Solids
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nano-particle delivery of brain derived neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances behavioral recovery
Harris M N, et al.
Pharmacology, Biochemistry, and Behavior, 150-151, 48-56 (2016)
Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities
Liu W, et al.
Neural Plast. (2020)
From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)
Geral C, et al.
Pharmaceutics, 5(1), 127-167 (2013)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service